Akebia Therapeutics AKBA Estimates

NASDAQ AKBA
$0.98 -0.05 (-4.57%)
As of: Sep 9, 2026 · 12:04 PM EDT
Analyst Estimates

Akebia Therapeutics, Inc. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 48.92 M

Analysts expect Akebia Therapeutics, Inc. to report revenue of 48.92 M for Q3 26, against a range of 44.26 M to 53.58 M. The most recent reported quarter, Q2 26, came in at 49.13 M, a 3.7% miss against the 51.00 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 37.43 M46.50 M57.34 M62.47 M58.77 M57.62 M53.54 M49.13 M--------
High Estimate 50.31 M39.79 M46.34 M50.34 M57.72 M46.34 M58.05 M55.59 M53.58 M48.23 M32.72 M37.16 M43.54 M43.66 M44.05 M49.18 M
Low Estimate 43.78 M33.33 M40.48 M42.02 M53.63 M42.34 M51.29 M46.41 M44.26 M41.17 M29.94 M31.04 M36.92 M38.54 M38.19 M40.43 M
Consensus Estimate 47.04 M36.56 M43.41 M46.18 M55.67 M44.34 M54.67 M51.00 M48.92 M44.70 M31.33 M34.10 M40.23 M41.10 M41.12 M44.80 M
Analyst Estimates

Akebia Therapeutics, Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -0.04

Analysts expect Akebia Therapeutics, Inc. to report earnings per share of -0.04 for Q3 26, against a range of -0.04 to -0.04. The most recent reported quarter, Q2 26, came in at -0.03, a 25.0% beat against the -0.04 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.10-0.100.030.000.00-0.05-0.03-0.03--------
High Estimate -0.06-0.07-0.04-0.02-0.01-0.04-0.03-0.04-0.04-0.05-0.10-0.09-0.07-0.08-0.04-0.05
Low Estimate -0.06-0.07-0.04-0.02-0.01-0.04-0.03-0.04-0.04-0.05-0.10-0.09-0.07-0.08-0.04-0.05
Consensus Estimate -0.06-0.07-0.04-0.02-0.01-0.04-0.03-0.04-0.04-0.05-0.10-0.09-0.07-0.08-0.04-0.05